Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
VOR · Why this verdict
Why Vor Biopharma (VOR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality sits far below the engine's 4.0 floor at 1.5, driven by a cash-burning FCF profile, zero margins, and a weak Piotroski F-Score of 2/9, triggering an exit-position action note. Quality breakdown | FCF should turn less negative and the Piotroski F-Score should climb toward 4+ over the next 12 months if the underlying business is stabilizing. | →Stable |
| CounterPre-revenue biotech companies are expected to burn cash while advancing a pipeline; a low Piotroski score is a poor proxy for clinical-stage progress or catalyst-driven value creation. | ||
Vor Biopharma clears the engine's asymmetry gate at a 4.0 ratio, with an analyst-target-based upside of 60% against a modeled 7% downside to stop-loss, reflecting a speculative but statistically favorable risk/reward setup. Reward-to-risk math | The stock should approach the analyst-target take-profit of $32.95 (from $20.59) within 12 months if the asymmetry thesis holds. | →Stable |
| CounterAnalyst targets on binary biotech names with wildly volatile earnings surprises (avg surprise +5258%, reflecting near-zero estimate bases) are unreliable anchors for a 60% upside call. | ||
The engine's insider gate failed at an EXTREME 4.004% of market cap ($44,674,252) sold over 90 days across 13 transactions with zero buys, the most severe insider-selling classification in the framework. Engine gate (failed) | Insider selling severity should de-escalate from EXTREME toward MODERATE or lower, with net selling below 2% of market cap, over the next 12 months. | →Stable |
| CounterLarge aggregate insider selling in a name that just rallied sharply (RSI 84, volume surge 2.4x average) may reflect routine profit-taking after a run-up rather than a considered negative view on pipeline value. | ||
The engine classifies the setup as RECOVERY - a prior death cross with MACD improving and RSI at 84 - alongside a momentum score of 8.3, the highest of the ten scoring dimensions. Momentum breakdown | Price should sustain a move back above the 200-day moving average with MACD continuing to improve over the next 12 months, confirming the recovery. | →Stable |
| CounterAn RSI of 84 alongside a flat-to-negative 200-day moving-average slope is explicitly flagged as late-cycle distribution risk, meaning the 'recovery' could just be a short-covering spike that reverses. | ||
The stock is down 69% from its 52-week high and classified SPECULATIVE due to binary biotech industry risk, meaning the investment case hinges on a small number of high-stakes catalysts. Suitability rationale | The drawdown should narrow (price recovering toward less than 40% off the 52-week high) as clinical or regulatory catalysts materialize over the next 12 months. | →Stable |
| CounterBinary clinical-stage biotech names can just as easily gap down further on a single trial or regulatory setback, making the current 69% drawdown a floor that isn't guaranteed to hold. | ||
Quality sits far below the engine's 4.0 floor at 1.5, driven by a cash-burning FCF profile, zero margins, and a weak Piotroski F-Score of 2/9, triggering an exit-position action note.
→StableQuality breakdown
- Expectation
- FCF should turn less negative and the Piotroski F-Score should climb toward 4+ over the next 12 months if the underlying business is stabilizing.
CounterPre-revenue biotech companies are expected to burn cash while advancing a pipeline; a low Piotroski score is a poor proxy for clinical-stage progress or catalyst-driven value creation.
Vor Biopharma clears the engine's asymmetry gate at a 4.0 ratio, with an analyst-target-based upside of 60% against a modeled 7% downside to stop-loss, reflecting a speculative but statistically favorable risk/reward setup.
→StableReward-to-risk math
- Expectation
- The stock should approach the analyst-target take-profit of $32.95 (from $20.59) within 12 months if the asymmetry thesis holds.
CounterAnalyst targets on binary biotech names with wildly volatile earnings surprises (avg surprise +5258%, reflecting near-zero estimate bases) are unreliable anchors for a 60% upside call.
The engine's insider gate failed at an EXTREME 4.004% of market cap ($44,674,252) sold over 90 days across 13 transactions with zero buys, the most severe insider-selling classification in the framework.
→StableEngine gate (failed)
- Expectation
- Insider selling severity should de-escalate from EXTREME toward MODERATE or lower, with net selling below 2% of market cap, over the next 12 months.
CounterLarge aggregate insider selling in a name that just rallied sharply (RSI 84, volume surge 2.4x average) may reflect routine profit-taking after a run-up rather than a considered negative view on pipeline value.
The engine classifies the setup as RECOVERY - a prior death cross with MACD improving and RSI at 84 - alongside a momentum score of 8.3, the highest of the ten scoring dimensions.
→StableMomentum breakdown
- Expectation
- Price should sustain a move back above the 200-day moving average with MACD continuing to improve over the next 12 months, confirming the recovery.
CounterAn RSI of 84 alongside a flat-to-negative 200-day moving-average slope is explicitly flagged as late-cycle distribution risk, meaning the 'recovery' could just be a short-covering spike that reverses.
The stock is down 69% from its 52-week high and classified SPECULATIVE due to binary biotech industry risk, meaning the investment case hinges on a small number of high-stakes catalysts.
→StableSuitability rationale
- Expectation
- The drawdown should narrow (price recovering toward less than 40% off the 52-week high) as clinical or regulatory catalysts materialize over the next 12 months.
CounterBinary clinical-stage biotech names can just as easily gap down further on a single trial or regulatory setback, making the current 69% drawdown a floor that isn't guaranteed to hold.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Vor Biopharma screens as a high-asymmetry, momentum-recovering speculative biotech (4.0 asymmetry ratio, 60% modeled upside) but carries a quality score far below the engine's floor, an EXTREME insider-selling gate failure, and a 69% drawdown that keep the setup firmly in binary-catalyst territory.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.9 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 4.5 |
- ▸Overbought (RSI 82)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 82 (late-cycle distribution risk)
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.0 |
| Analyst rating | 5.0 |
| Price target | 9.9 |
- ▸Analyst upside: 86%
Insider
4.7/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
- ▸Heavy insider selling — $26,918,569 (2.472% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.1 |
| support resistance | 2.0 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
2.7/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 3.4 |
| days to cover | 3.1 |
| volatility | 0.0 |
| beta | 4.4 |
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.2>=5.5
- ASYMMETRY:4.2>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:38d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- INSIDER:2.47%=EXTREME
Warning (1)
- DEATH_CROSS:momentum=7.2>=5.0 recovering
Reward-to-Risk
4.15
Upside
+62.2%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 82
EdgeInst Constrain — Small cap ($1.1B) below institutional reach
SuitabilitySpeculative — Drawdown -69% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor. Failed gate signal: INSIDER:2.47%=EXTREME.
The strongest dimensions are Value at 9.0, Momentum at 7.2, and Sentiment at 6.8; the weakest are Quality at 1.5, Technical at 2.3, and Risk (lower is worse) at 2.7. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 4.15 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Asymmetry Analyst Upside
Trip ifAsymmetry ratio falls below 1.5 from the current 4.0, or price fails to close above $25 within 12 months.
- P2Quality Below Floor Cash Burning
Trip ifPiotroski F-Score rises above 4 from the current 2.2, or FCF quality component exceeds 3.0.
- P3Extreme Insider Selling Gate Failure
Trip ifInsider selling as a percentage of market cap exceeds 6% over a rolling 90-day window, up from the current 4.004%.
- P4Technical Recovery From Death Cross
Trip ifRSI falls below 50 within 3 months without a corresponding higher low in price, or the stock closes back below its 200-day moving average.
- P5Deep Drawdown Binary Biotech Risk
Trip ifDrawdown from the 52-week high exceeds 80%, worse than the current 69%.